Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates

June 25, 2021

View Press Release Corporate presentation Contact us
Previous